Orexigen Insists Revised Contrave Data Should Not Affect Review Timeline

Although Orexigen Therapeutics needed to correct data included in the NDA for its Contrave obesity drug, the company appears to have weathered some shareholder concern and may be on an unchanged timeline for FDA consideration and approval of its application

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet